Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland

Show full item record



Permalink

http://hdl.handle.net/10138/302382

Citation

Purmonen , T , Puolakka , K , Mishra , D , Gunda , P & Martikainen , J 2019 , ' Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland ' , ClinicoEconomics and outcomes research , vol. 11 , pp. 159-168 . https://doi.org/10.2147/CEOR.S192235

Title: Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
Author: Purmonen, Timo; Puolakka, Kari; Mishra, Dinesh; Gunda, Praveen; Martikainen, Janne
Contributor: University of Helsinki, HYKS erva
Date: 2019
Language: eng
Number of pages: 10
Belongs to series: ClinicoEconomics and outcomes research
ISSN: 1178-6981
URI: http://hdl.handle.net/10138/302382
Abstract: Aim: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab in a biologic-naive population over a lifetime horizon. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were obtained from the network meta-analysis, and other model inputs were obtained from the published literature and Finnish sources. Main study outcomes included quality-adjusted life years (QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses. Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost (ss279,872) vs other comparators in biologic-naive AS patients in the base case analysis, thus it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of ss309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, baseline Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. Secukinumab was either dominant or cost-effective treatment in different alternative scenarios. Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effective) treatment vs other comparators for the biologic-naive patients with AS in Finland.
Subject: radiographic axial SpA
secukinumab
cost-effectiveness
Finland
economic evaluation
health economics
IL-17
anti-TNF
POPULATION-BASED COHORT
AXIAL SPONDYLOARTHRITIS
WORK PRODUCTIVITY
DISEASE-ACTIVITY
A INHIBITORS
AGENTS
MORTALITY
EFFICACY
BURDEN
DRUGS
3141 Health care science
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ceor_192235_cos ... _other_biologic_021419.pdf 254.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record